EGFR Inhibitors in 2026: Types, Drugs, EGFR Mutations, Resistance & Lung Cancer Treatment

Article type: Narrative evidence review

Last medically reviewed: October 26, 2026

Scope: EGFR-targeted therapy in non-small cell lung cancer (NSCLC), with emphasis on mutation-specific treatment, sunvozertinib and acquired resistance.

Abstract

Background: Epidermal growth factor receptor (EGFR) inhibitors are established components of precision treatment for selected patients with non-small cell lung cancer (NSCLC). Their effectiveness depends on the precise EGFR alteration, disease setting, prior therapies, resistance mechanisms and patient characteristics. EGFR exon 20 insertion mutations constitute a biologically distinct subgroup that historically responded less reliably to conventional EGFR tyrosine kinase inhibitors (TKIs).

Objective: To review major EGFR inhibitor classes, clinically relevant mutations, treatment selection, acquired resistance and the evolving role of sunvozertinib in EGFR exon 20 insertion–positive NSCLC.

Evidence review: This narrative update synthesizes regulatory information, peer-reviewed clinical trials, the 2026 phase III WU-KONG28 publication, and contemporary professional guidance available through October 26, 2026. It is not a systematic review or an independent meta-analysis.

Findings: Osimertinib remains a major treatment option for common sensitizing EGFR mutations, including exon 19 deletions and L858R. Selected patients may also be candidates for combination regimens, including amivantamab plus lazertinib. For EGFR exon 20 insertion–positive advanced NSCLC, treatment options include amivantamab-based therapy and sunvozertinib, subject to treatment setting, regulatory status and local access. In WU-KONG28, first-line sunvozertinib improved median progression-free survival compared with platinum-based chemotherapy, although overall survival data remained immature at the reported analysis. The U.S. FDA-labeled sunvozertinib indication remains narrower than this emerging first-line evidence.

Conclusion: EGFR treatment should be mutation-specific and reassessed as the disease evolves. Molecular testing, accurate interpretation of the variant, toxicity monitoring and investigation of resistance are essential to informed treatment selection.

Keywords: EGFR inhibitors; EGFR mutations; non-small cell lung cancer; osimertinib; sunvozertinib; EGFR exon 20 insertion; amivantamab; acquired resistance; precision oncology.

---

Clinical summary: What matters in 2026

• The exact mutation matters. Exon 19 deletions, L858R, uncommon EGFR variants and exon 20 insertions should not be treated as interchangeable biomarkers.
• Osimertinib remains central to treatment of common sensitizing EGFR mutations. Additional options and combination regimens depend on the individual clinical setting.
• Sunvozertinib is an important exon 20 insertion–directed therapy. The FDA granted accelerated U.S. approval on July 2, 2025, for eligible adults whose locally advanced or metastatic NSCLC progressed during or after platinum-based chemotherapy.
• First-line evidence has advanced. WU-KONG28 demonstrated superior progression-free survival versus platinum-based chemotherapy, and the 2026 ASCO living guideline includes first-line sunvozertinib monotherapy as an option.
• Guideline recommendations and regulatory labels are not interchangeable. The FDA-labeled indication, local product approval, guideline recommendations and reimbursement rules must be checked separately.
• Resistance requires investigation. Repeat tissue or plasma molecular testing may identify a new target or reveal a different disease process, including histologic transformation.

1. Introduction: What are EGFR inhibitors?

EGFR stands for epidermal growth factor receptor, a receptor tyrosine kinase involved in signaling pathways that regulate cell growth, survival and proliferation.

In some cancers, activating genetic alterations make tumor cells unusually dependent on EGFR signaling. EGFR-targeted therapies inhibit this pathway, potentially producing tumor shrinkage, delaying disease progression and extending disease control.

EGFR inhibitors are particularly important in NSCLC, especially lung adenocarcinoma. However, an EGFR-positive result is not sufficient by itself to select a drug. EGFR protein expression, gene amplification and specific activating EGFR mutations are different biological findings. The relevant biomarker and clinical evidence must match the treatment being considered.

Several categories of EGFR-directed therapy are used in modern oncology:

• Small-molecule EGFR TKIs: Oral drugs that inhibit intracellular kinase signaling.
• Mutation-selective TKIs: Drugs developed to inhibit particular mutant EGFR forms, including exon 20 insertion variants.
• EGFR-directed antibodies: Treatments such as amivantamab that bind cell-surface targets and act through mechanisms distinct from oral TKIs.
• Combination regimens: Strategies combining targeted agents with chemotherapy or other targeted therapies.

The choice among these approaches depends on the molecular diagnosis, disease stage, prior treatment, central nervous system involvement, comorbidities, treatment burden and patient preferences.

2. Which EGFR mutations matter?

EGFR-mutated NSCLC is not a single molecular disease. Different mutations affect receptor structure and drug sensitivity in different ways.

EGFR alteration	Clinical significance	Treatment implications
Exon 19 deletion	Common sensitizing EGFR alteration.	Osimertinib and other evidence-supported regimens may be considered according to stage and treatment setting.
Exon 21 L858R	Common sensitizing EGFR point mutation.	Established EGFR-targeted options include osimertinib and, for appropriate patients, certain combination regimens.
EGFR exon 20 insertion	A heterogeneous group of insertions with distinct structural and pharmacological characteristics.	Requires mutation- and setting-specific treatment assessment. Options include sunvozertinib and amivantamab-based regimens.
G719X, S768I, L861Q and other uncommon variants	Sensitivity varies by specific variant and by whether multiple alterations coexist.	Treatment should follow mutation-specific clinical evidence rather than assumptions based on the EGFR gene alone.
T790M	An important acquired resistance mutation after certain earlier-generation EGFR TKIs.	Osimertinib has established activity against T790M-positive disease in the appropriate treatment setting.
C797S and other resistance alterations	Can interfere with drug binding or activate alternative routes of tumor growth.	May prompt repeat molecular profiling, a different treatment strategy or clinical-trial assessment.

The most important practical distinction is between common sensitizing EGFR mutations and exon 20 insertions. Conventional EGFR TKIs that work well for exon 19 deletion or L858R disease should not automatically be assumed to work equally well for exon 20 insertion–positive tumors.

3. Types of EGFR inhibitors

3.1 First-generation EGFR TKIs

Examples: gefitinib and erlotinib.

These reversible inhibitors were foundational treatments for molecularly selected EGFR-mutated NSCLC. Their current role depends on local approvals, the specific mutation, available newer therapies and whether resistance has emerged.

3.2 Second-generation EGFR TKIs

Examples: afatinib and dacomitinib.

These agents inhibit EGFR-family signaling irreversibly. They remain relevant in selected clinical settings, including particular EGFR mutation profiles, but their toxicity and comparative evidence should be considered when selecting treatment.

3.3 Third-generation EGFR TKIs

Example: osimertinib.

Osimertinib is an important treatment for common sensitizing EGFR mutations and has activity against T790M-positive disease in the appropriate setting. Its central nervous system activity is an important consideration for patients with brain metastases.

For eligible patients with common sensitizing EGFR mutations, current treatment strategies may include osimertinib alone, osimertinib combined with platinum-based chemotherapy, or lazertinib combined with amivantamab. These regimens have different efficacy, toxicity and practical considerations; there is no single regimen that is optimal for every patient.

3.4 EGFR-directed antibodies

Example: amivantamab.

Amivantamab is a bispecific antibody directed against EGFR and MET. It is not an oral EGFR TKI. It has an important role in selected EGFR-mutated NSCLC settings, including EGFR exon 20 insertion–positive disease.

For eligible patients with previously untreated advanced NSCLC harboring EGFR exon 20 insertions, amivantamab combined with carboplatin and pemetrexed is an established U.S. FDA-approved first-line option. Its eligibility criteria, infusion or administration requirements, and adverse-effect profile differ from those of an oral TKI.

3.5 Mutation-selective inhibition: sunvozertinib

Sunvozertinib, also known as DZD9008 and marketed in the United States as Zegfrovy, is an oral EGFR TKI developed for EGFR exon 20 insertion–positive NSCLC.

Its development is important because exon 20 insertions have historically presented a treatment challenge: the altered kinase structure often limits the effectiveness of conventional EGFR inhibitors used for common sensitizing mutations.

Sunvozertinib should therefore be discussed as a mutation-directed option, not as a universal replacement for osimertinib or as a drug that treats every EGFR alteration.

4. Sunvozertinib: Clinical evidence and regulatory status

4.1 U.S. FDA approval and current indication

On July 2, 2025, the U.S. Food and Drug Administration granted accelerated approval to sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations detected by an FDA-approved test, when the disease has progressed on or after platinum-based chemotherapy.

The approval was supported by the WU-KONG1B clinical trial. The FDA's efficacy analysis included 85 patients treated with sunvozertinib 200 mg orally once daily with food. The confirmed objective response rate was 46% (95% confidence interval [CI], 35%–57%), and the median duration of response was 11.1 months (95% CI, 8.2 months to not estimable).

This is clinically meaningful evidence of antitumor activity in a previously treated population, but response rate and duration of response are not the same as proof of improved overall survival.

Official sources:

• FDA accelerated approval announcement
• FDA prescribing information for Zegfrovy
• Peer-reviewed WU-KONG1B phase II publication

4.2 WU-KONG28: Phase III first-line evidence

The phase III WU-KONG28 trial evaluated sunvozertinib against platinum-based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertions who had not received systemic treatment for advanced disease.

The randomized trial enrolled 324 patients. Its findings, published in the New England Journal of Medicine in 2026, reported:

Outcome	Sunvozertinib	Platinum-based chemotherapy
Median progression-free survival	10.3 months	7.5 months
Hazard ratio for progression or death	0.65 (95% CI, 0.50–0.85; P < 0.001)
Objective response rate	58.9%	31.1%
Median duration of response	11.2 months	7.1 months
Grade 3 or higher adverse events	75.5%	56.7%

Interpretation: Sunvozertinib significantly improved median progression-free survival relative to the chemotherapy comparator in this phase III trial. The hazard ratio of 0.65 indicates a lower instantaneous risk of progression or death during the study among patients assigned to sunvozertinib; it does not mean that every patient gained the same number of months or had a 35% increase in lifespan.

Overall survival data were immature at the reported analysis. Consequently, the results should not be described as proof that sunvozertinib improves overall survival or cures EGFR exon 20 insertion–positive lung cancer.

Grade 3 or higher adverse events were reported more frequently in the sunvozertinib group than in the chemotherapy group. Increased creatine kinase, diarrhea and anemia were among the common severe adverse events in the sunvozertinib group. These data reinforce the importance of active toxicity monitoring even when a targeted drug is taken orally.

Primary publication: Zhou C, et al. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. New England Journal of Medicine. 2026;395:765–775. PubMed record. DOI: 10.1056/NEJMoa2604461.

4.3 First-line guideline recommendations versus FDA labeling

The 2026 ASCO living guideline for stage IV NSCLC with driver alterations includes sunvozertinib monotherapy or platinum-doublet chemotherapy combined with amivantamab among the first-line options for eligible patients with EGFR exon 20 insertion–positive disease.

However, clinical guideline recommendations and formal regulatory indications are not identical. As of October 26, 2026, the U.S. FDA-labeled indication for sunvozertinib remains in the setting of disease progression on or after platinum-based chemotherapy. The FDA continues to list a confirmatory-trial requirement for this accelerated approval.

The first-line trial evidence therefore matters for clinical decision-making, but the U.S. indication should not be described as already expanded unless the FDA updates the approved labeling. Regulatory status, reimbursement and access may differ in other countries, including Malaysia.

Read the 2026 ASCO living guideline and the FDA list of ongoing cancer accelerated approvals.

4.4 An important dosing distinction

The current U.S. labeled dose for the previously treated indication is 200 mg orally once daily with food, continued until disease progression or unacceptable toxicity, with dose modifications managed according to the prescribing information.

The first-line WU-KONG28 trial used a different study regimen. Its trial record lists sunvozertinib at 300 mg once daily. The first-line trial dose must not be substituted automatically for the current U.S. labeled dose or applied to an individual patient without the treating oncology team's direction.

For safety, dosing decisions must follow the applicable local prescribing information and the oncologist's assessment. Patients should not adjust the dose or change treatment based solely on results from a clinical trial conducted in a different treatment setting.

4.5 What these results do not establish

• They do not establish that sunvozertinib works for every EGFR mutation.
• They do not show that sunvozertinib is superior to every other exon 20 insertion treatment, because WU-KONG28 compared it with platinum-based chemotherapy, not with all other targeted regimens.
• They do not establish a mature overall survival benefit in the reported first-line analysis.
• They do not eliminate the need for biomarker confirmation, toxicity monitoring or reassessment at progression.
• They do not mean that regulatory approval or reimbursement is identical in every country.

5. How do major EGFR-targeted treatments compare?

Treatment	Drug class	Relevant setting	Key consideration
Osimertinib	Third-generation EGFR TKI	Common sensitizing mutations; selected other settings	Established activity in exon 19 deletion and L858R disease, including important CNS activity.
Lazertinib + amivantamab	EGFR TKI plus EGFR/MET-directed antibody	Selected first-line advanced NSCLC with common sensitizing EGFR mutations	Different administration and adverse-effect profile from oral TKI monotherapy.
Amivantamab + carboplatin + pemetrexed	Antibody plus chemotherapy	First-line advanced EGFR exon 20 insertion–positive NSCLC in the approved setting	Combination treatment with chemotherapy-associated and antibody-associated risks.
Sunvozertinib	Mutation-directed oral EGFR TKI	FDA-labeled use after progression on or after platinum chemotherapy; first-line evidence now available	Check the exact mutation, local approval, treatment setting, dose and safety requirements.
Afatinib	Second-generation ErbB-family TKI	Selected EGFR-mutated NSCLC, including certain uncommon variants	Mutation-specific evidence and risks such as diarrhea and skin toxicity matter.

This is a framework for understanding treatment categories, not a direct comparative ranking. Cross-trial comparisons of response rates or survival can be misleading because studies differ in eligibility, prior treatment, mutation subtype, follow-up duration and endpoint assessment.

6. EGFR mutation testing: A critical first step

Appropriate molecular testing is essential before selecting a mutation-directed treatment. In advanced nonsquamous NSCLC, comprehensive genomic testing can identify actionable EGFR alterations and other potential treatment targets.

6.1 Tissue biopsy and liquid biopsy

Tissue-based testing can establish tumor histology and identify genomic alterations. Depending on the sample and testing platform, results may be obtained through targeted mutation testing or broader next-generation sequencing.

Liquid biopsy analyzes circulating tumor DNA (ctDNA) in blood. It can sometimes identify actionable alterations without another invasive tissue biopsy and may be particularly useful when tumor tissue is difficult to obtain.

A negative plasma ctDNA result does not necessarily rule out an actionable mutation. The tumor may release insufficient DNA into the bloodstream for detection. When clinically appropriate, tissue testing may therefore still be necessary after a negative or inconclusive plasma result.

6.2 What to verify on the molecular report

• The exact EGFR variant, including the exon and specific alteration.
• Whether the variant is established as actionable for the proposed drug and treatment setting.
• Whether multiple EGFR alterations or other relevant genomic findings are present.
• The testing method and any limitations of the assay.
• Whether a companion diagnostic is required by the relevant regulator.

For sunvozertinib in the United States, the FDA indication specifies an EGFR exon 20 insertion detected by an FDA-approved test. An EGFR result should not be interpreted as treatment eligibility without checking the precise variant and current applicable labeling.

7. Why do EGFR inhibitors stop working?

Acquired resistance is a major challenge in advanced EGFR-mutated NSCLC. Even when a treatment initially controls the cancer, tumor cells can evolve under the selective pressure of therapy. Resistant cell populations may have been present before treatment or may emerge during disease progression.

7.1 Major resistance mechanisms

Resistance mechanism	What happens	Potential clinical implication
EGFR T790M	A secondary EGFR mutation that can confer resistance to earlier-generation EGFR TKIs.	May identify an indication for a T790M-active drug in the appropriate clinical setting.
EGFR C797S	Can interfere with the covalent binding mechanism used by several third-generation inhibitors.	Requires molecular interpretation; potential next-generation treatments remain dependent on the precise resistance profile and clinical evidence.
MET amplification	An alternative growth pathway can bypass EGFR inhibition.	May inform a biomarker-directed combination strategy or clinical-trial consideration.
HER2 or other bypass alterations	Alternative signaling pathways reduce dependence on the original EGFR target.	Additional genomic evaluation may help characterize the resistance mechanism.
Histologic transformation	The tumor changes its cellular phenotype; some EGFR-mutated cancers transform to small-cell lung cancer.	Repeat tissue biopsy may be especially valuable because genomic testing alone may not establish the changed histology.
Polyclonal resistance	Different tumor subclones develop different resistance mechanisms.	A single biopsy or blood test may not capture the complete disease picture.

7.2 What should happen when an EGFR inhibitor stops working?

Progression should trigger a structured reassessment rather than an automatic switch to another EGFR inhibitor.

1. Confirm the pattern of progression. Imaging, symptoms and clinical assessment help distinguish generalized progression from a limited number of progressing sites.
2. Review the original diagnosis and treatment history. Confirm the original EGFR variant, previous response, treatment duration and current medications.
3. Consider repeat molecular profiling. Plasma ctDNA, tissue biopsy or both may be appropriate, depending on the circumstances.
4. Look for histologic transformation when clinically indicated. Tissue examination can identify changes that a blood-based genomic test cannot fully characterize.
5. Match the next strategy to the new evidence. Potential options include an approved targeted therapy, chemotherapy, an antibody-based regimen, local treatment in selected circumstances or a clinical trial.

The optimal sequence of therapies is not established for every resistance profile. Repeat testing can provide valuable information, but it does not guarantee that a new actionable alteration will be found or that a more effective treatment will be available.

8. EGFR inhibitor side effects and safety monitoring

EGFR-directed drugs differ in their mechanisms and adverse-effect profiles. They can be easier to tolerate than some cytotoxic regimens for certain patients, but targeted therapy is not risk-free.

8.1 Common adverse effects across EGFR TKIs

• Diarrhea.
• Acneiform rash, dry skin and itching.
• Nail inflammation, including paronychia.
• Mouth sores or stomatitis.
• Nausea, vomiting and reduced appetite.
• Fatigue.
• Changes in liver enzymes or other laboratory measurements.

The specific frequency and severity depend on the drug, dose, treatment duration and individual patient. These adverse effects should not be assumed to occur at the same rate across different EGFR inhibitors.

8.2 Sunvozertinib-specific safety considerations

The FDA prescribing information for sunvozertinib includes warnings for:

• Interstitial lung disease (ILD) or pneumonitis: New or worsening cough, shortness of breath or fever warrants prompt assessment. The prescribing information directs clinicians to withhold the drug when ILD/pneumonitis is suspected and permanently discontinue it if confirmed.
• Gastrointestinal toxicity: Diarrhea, nausea, vomiting and related symptoms may require supportive treatment, hydration, interruption or dose modification.
• Skin and nail reactions: Rash and other dermatologic adverse effects require appropriate monitoring and management.
• Ocular toxicity: New visual symptoms should be reported and assessed.
• Embryo-fetal toxicity: Pregnancy-related precautions apply; the current prescribing information should be consulted.

Laboratory abnormalities reported in clinical studies include increased creatine kinase and changes in blood counts, electrolytes, pancreatic enzymes and liver-associated tests. Monitoring should follow the product information and the treating oncology team's protocol.

Patients should contact their oncology team promptly about new respiratory symptoms, persistent or severe diarrhea, significant dehydration, marked skin reactions or visual symptoms. Severe or rapidly worsening breathing difficulty requires urgent medical assessment.

Do not stop, restart or adjust an anticancer drug without medical guidance, except where emergency instructions from the treating team or prescribing information specifically require immediate action.

Source: FDA Zegfrovy prescribing information.

9. EGFR inhibitors and brain metastases

Brain metastases are an important consideration in NSCLC because the central nervous system can be a site of progression even when disease elsewhere is controlled.

Osimertinib is particularly important in common EGFR-mutated NSCLC because of its established central nervous system activity. Treatment decisions should nevertheless consider the extent and location of intracranial disease, neurologic symptoms, available evidence for the specific drug and the need for local treatment.

Results from a general response-rate analysis should not automatically be interpreted as proof of equivalent intracranial efficacy. For exon 20 insertion–positive disease, clinicians should assess brain metastases and review the evidence for the proposed systemic regimen rather than assuming that results from common EGFR mutations apply equally.

10. EGFR inhibitors and combination therapy

Combination approaches aim to improve disease control through complementary mechanisms or to address resistance. They may combine an EGFR TKI with chemotherapy, an EGFR/MET-directed antibody with chemotherapy, or other agents in selected clinical settings.

Combination treatment can also increase toxicity, complexity, cost and monitoring requirements. The clinically relevant question is not whether a regimen uses more drugs, but whether the expected benefits justify its risks for the particular patient.

Examples of evidence-based strategies include:

• Osimertinib-based treatment for eligible common sensitizing EGFR mutations.
• Selected first-line regimens combining EGFR-directed agents with chemotherapy or antibodies for appropriate EGFR-mutated NSCLC.
• Amivantamab plus carboplatin and pemetrexed for eligible first-line EGFR exon 20 insertion–positive advanced NSCLC.
• Sunvozertinib for its labeled setting and consideration in first-line decision-making as supported by emerging phase III evidence and current professional guidance.

Investigational fourth-generation EGFR inhibitors and resistance-directed combinations should be distinguished from established approved therapies. Availability in a clinical trial does not mean a strategy has been proven to improve outcomes or is appropriate for routine off-trial use.

11. The future of EGFR-targeted therapy

11.1 Mutation-selective drugs

Sunvozertinib's development illustrates the move toward drugs designed for specific EGFR mutation subgroups rather than a single treatment strategy for every EGFR alteration. Further research is needed to determine how the different exon 20 insertion variants affect sensitivity, durability and resistance.

11.2 Fourth-generation inhibitors

Fourth-generation EGFR inhibitors are being investigated to address difficult resistance mechanisms, including certain C797S-containing tumors. These agents remain investigational unless and until the relevant regulatory authorities approve them for a defined indication.

11.3 Longitudinal molecular monitoring

Serial ctDNA testing may help identify changes in tumor genetics during treatment. However, its usefulness depends on tumor DNA shedding, assay performance, the specific alteration and whether identifying the result would change management.

Blood-based molecular monitoring should complement, not automatically replace, imaging, clinical assessment and tissue evaluation when histologic transformation or another tissue-dependent question is suspected.

11.4 Treatment sequencing

As more mutation-directed drugs become available, the challenge increasingly involves choosing the right treatment at the right point in the disease course. Future studies need to compare sequencing strategies, evaluate overall survival and quality of life, characterize resistance after newer agents, and examine treatment burden as well as tumor response.

12. Evidence interpretation and limitations

Clinical trial findings must be interpreted within their study design and population.

• Objective response rate measures the proportion of patients whose tumors shrink by a predefined amount. It does not establish a survival benefit by itself.
• Progression-free survival measures the time until disease progression or death under a study's definition. It is not equivalent to overall survival.
• Overall survival directly evaluates time to death, but requires adequate follow-up and event maturity to estimate reliably.
• Adverse-event comparisons depend on trial design, exposure duration, patient selection and the definitions used to classify severity.
• Regulatory status is jurisdiction-specific. FDA approval should not be presented as proof of approval in every country.

WU-KONG28 was sponsored by Dizal Pharmaceuticals, the developer of sunvozertinib. Its randomized phase III design and peer-reviewed publication support evaluation of its efficacy results, while transparent reporting of sponsorship, comparator choice, adverse events and immature overall survival data remains important to balanced interpretation.

This article is a narrative evidence review intended for education. It does not independently reanalyze participant-level data and is not a formal systematic review, clinical practice guideline or substitute for individualized medical advice.

13. Frequently asked questions

What is the best EGFR inhibitor for lung cancer?

There is no single best EGFR inhibitor for every patient. For common sensitizing EGFR mutations such as exon 19 deletion and L858R, osimertinib remains a major treatment option, with other approved regimens available for eligible patients. EGFR exon 20 insertions require a different treatment assessment, including consideration of sunvozertinib and amivantamab-based therapy.

Is sunvozertinib FDA approved?

Yes. The FDA granted accelerated approval to sunvozertinib (Zegfrovy) on July 2, 2025, for adults with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The approval is based on response rate and duration of response, with confirmatory evidence required.

Can sunvozertinib be used as first-line treatment?

The phase III WU-KONG28 trial demonstrated improved progression-free survival compared with platinum-based chemotherapy in the first-line setting. The 2026 ASCO living guideline includes sunvozertinib monotherapy as a first-line option for eligible patients. However, as of October 26, 2026, the U.S. FDA-labeled indication remains for disease progressing during or after platinum-based chemotherapy. Local regulatory status and access must be checked.

Does sunvozertinib work for every EGFR mutation?

No. Its U.S. indication is for NSCLC with EGFR exon 20 insertion mutations detected by an FDA-approved test. It should not be assumed to be appropriate for exon 19 deletions, L858R, T790M or other EGFR alterations without a specific evidence-supported indication.

Is sunvozertinib better than amivantamab?

The available evidence does not establish universal superiority of one over the other. WU-KONG28 compared first-line sunvozertinib with platinum-based chemotherapy, not directly with amivantamab-based treatment. Treatment selection requires consideration of the patient's setting, clinical characteristics, efficacy evidence, adverse effects, regulatory status and preferences.

Does a higher response rate mean a longer life?

Not necessarily. Response rate measures tumor shrinkage, while progression-free survival and overall survival measure different outcomes. WU-KONG28 demonstrated improved progression-free survival, but overall survival was immature at the reported analysis. Further follow-up is needed to better characterize survival outcomes.

Why does EGFR-targeted therapy stop working?

Resistance may arise through new EGFR mutations, alternative growth pathways such as MET amplification, changes in tumor histology or the emergence of different resistant tumor subclones. Repeat molecular profiling and, where indicated, tissue biopsy may help guide the next treatment decision.

Should EGFR testing be repeated after progression?

Repeat tissue or plasma testing may be useful when the result could influence treatment. The choice depends on the original molecular findings, clinical pattern of progression, available tissue, limitations of plasma testing and the possibility of histologic transformation. A negative plasma result does not exclude every actionable alteration.

Is sunvozertinib a cure for EGFR exon 20 insertion–positive lung cancer?

No. The trial evidence supports antitumor activity and improved progression-free survival in the studied settings, but it does not establish a cure. In advanced NSCLC, targeted therapies are generally used to control disease and prolong survival, while ongoing monitoring and subsequent treatment may still be necessary.

14. Conclusion

EGFR-targeted therapy has evolved from broad first-generation kinase inhibition toward increasingly mutation-specific treatment strategies. Osimertinib remains central to the treatment of common sensitizing EGFR mutations, while exon 20 insertion–positive NSCLC requires its own evidence-based treatment pathway.

Sunvozertinib is one of the most important developments in this pathway. Its 2025 U.S. accelerated approval established a treatment option for eligible patients after platinum-based chemotherapy. The 2026 WU-KONG28 phase III results and updated ASCO guidance extend its importance into first-line treatment discussions. The distinction between this new clinical evidence and the current U.S. regulatory label must remain explicit.

For patients and clinicians, the practical framework is straightforward: identify the exact EGFR alteration, match treatment to the clinical setting, understand the evidence and regulatory limitations, monitor adverse effects, and investigate resistance when the disease progresses.

Medical disclaimer: This article is intended for educational purposes and does not replace individualized advice from a qualified oncology team. Drug approval, prescribing information and clinical guidelines may change. Treatment decisions should be based on the current applicable prescribing information and the patient's clinical circumstances.

---

References

1. U.S. Food and Drug Administration. FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. July 2, 2025. FDA announcement.
2. U.S. Food and Drug Administration. Zegfrovy (sunvozertinib) prescribing information. Official prescribing information.
3. Yang JCH, et al. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). Journal of Clinical Oncology. 2025;43(29):3198–3208. DOI: 10.1200/JCO-25-00788. PubMed.
4. Zhou C, et al. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. New England Journal of Medicine. 2026;395(8):765–775. DOI: 10.1056/NEJMoa2604461. PubMed.
5. American Society of Clinical Oncology. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3. Journal of Clinical Oncology guideline.
6. ClinicalTrials.gov. WU-KONG28: A Phase III study of sunvozertinib versus platinum-based doublet chemotherapy as first-line treatment for EGFR exon 20 insertion–positive NSCLC. NCT05668988. Trial registration and study record.
7. U.S. Food and Drug Administration. Ongoing cancer accelerated approvals. FDA regulatory-status tracker.

Review date: October 26, 2026. This narrative review reflects the cited evidence and regulatory information available on that date. Future publications, prescribing-information updates and regulatory decisions may change the treatment landscape.